These results show, for the first time, the effectiveness of a selective CXCR2 antagonist to improve insulin sensitivity, concomitantly preventing the progression towards LP characteristic of NAFLD/NASH. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.